BHCM
ABOS icon

Brevan Howard Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Brevan Howard Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,385
Closed -$36.3K – 2032
2026
Q1 		$36.3K Buy
+15,385
New +$39.2K ﹤0.01% 2104
2024
Q2 		– Sell
-56,369
Closed -$228K – 1023
2024
Q1 		$228K Buy
+56,369
New +$212K ﹤0.01% 750

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Brevan Howard Capital Management's ABOS Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Acumen Pharmaceuticals (ABOS) in Q2 2026, closing a stake of 15,385 shares — an estimated $36.3K sold.

Brevan Howard Capital Management first reported a position in ABOS in Q1 2024 and held it in 2 quarters. The position peaked at $228K in Q1 2024. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Acumen Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 15,385 Acumen Pharmaceuticals shares in Q2 2026, an estimated $36.3K.
  • Brevan Howard Capital Management first reported a position in Acumen Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Brevan Howard Capital Management's Acumen Pharmaceuticals position peaked at $228K in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.